NanoGhost is a biotech company that develops a highly selective first-in-class drug delivery platform (Nano-Ghosts/NGs) from the cell membrane of mesenchymal stem cells (MSCs), cells with known tropism to cancer and sites of inflammation. NanoGhost offers a novel, versatile, and highly selective targeted drug delivery platform for the treatment of oncological diseases. NanoGhosts can be loaded with various drug types, preserve MSCs tropism to cancer cells, and selectively penetrate tumors (including brain tumors while crossing the BBB and pancreatic cancer), leading to a major reduction in tumor size and prolonged survival.